Yesterday the FDA has granted Priority Review for entrectinib for the treatment of ROS1-positive NSCLC and NTRK fusion-positive solid tumors. The FDA is expected to make a decision on approval by August 18, 2019. FDA Grants Priority Review to Genentech’s Personalized Medicine Entrectinib
Tag: Entrectinib
Holy rash almighty
Holy rash almighty. Below is a graphic image for mature audiences only. Consider yourself warned. …continue reading…